International study on etiology of inhibitors in patients with a moderate or mild form of hemophilia A, influences of immunogenetic and hemophilia treatment factors.

International study on etiology of inhibitors in patients with a moderate or mild form of hemophilia A, influences of immunogenetic and hemophilia treatment factors. - INSIGHT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32171

Enrollment

Registered

2008-06-23

Start date

2012-11-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stollingsstoornissen bleeding disorder hemophilia A

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: mild/moderate hemophilia A (factor VIII 2-40%)

Exclusion criteria

Exclusion criteria: severe hemophilia A (factor VIII

Design outcomes

Primary

Measure	Time frame
- The incidence of inhibitor development in mild/moderate hemofilia A. - Clinical and genetic risk factors that promote inhibitor development in mild/moderate hemofilia A. - T-cell epitopes in patients with mild/moderate hemophilia A and inhibitory antibodies.	—

Countries

Netherlands

Outcome results